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Preterm birth (PTB) is one of the major health-care challenges of our time. Being born 
too early is associated with major risks to the child with potential for serious conse-
quences in terms of life-long disability and health-care costs. Discovering how to prevent 
PTB needs to be one of our greatest priorities. Recent advances have provided hope 
that a percentage of cases known to be related to risk factors may be amenable to 
prevention; but the majority of cases remain of unknown cause, and there is little chance 
of prevention. Applying the principle of precision public health may offer opportunities 
previously unavailable. Presented in this article are ideas that may improve our abilities 
in the fields of studying the effects of migration and of populations in transition, pub-
lic health programs, tobacco control, routine measurement of length of the cervix in 
mid-pregnancy by ultrasound imaging, prevention of non-medically indicated late PTB, 
identification of pregnant women for whom treatment of vaginal infection may be of 
benefit, and screening by genetics and other “omics.” Opening new research in these 
fields, and viewing these clinical problems through a prism of precision public health, 
may produce benefits that will affect the lives of large numbers of people.
Keywords: preterm birth, cervix length, progesterone, smoking, genomics, proteomics, transcriptomics, screening
iNTRODUCTiON
Preterm birth (PTB) is the single major cause of death in children up to 5 years of age in the 
developed world (1–3). In low-resource countries, early birth is the second greatest cause of death 
in young children, second only to pneumonia. Most children born too early will survive and go 
on to lead a normal and healthy life, but for many there will be life-long disability. Health issues 
may include neurodevelopmental delay, hearing and visual loss, cerebral palsy, and learning and 
behavioral problems. The potential impact on individuals, families, and society are considerable 
(4, 5).
Providing optimal care for very preterm infants in dedicated neonatal intensive care units is 
vital to minimize any potential for life-long harm, but such care comes at considerable financial 
cost. The potential costs to society in terms of lost productivity throughout the lifespan may be 
even greater (6). Considerable benefit has arisen from the discovery in 1972 that administration 
of corticosteroids to the mother at risk of early birth will halve the rate of death and respiratory 
distress syndrome in the preterm newborn, but the treatment does not in itself delay the age at 
birth (7, 8).
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Preterm birth is defined as birth before 37 and after 20 com-
pleted weeks of gestation. There are many potential pathways to 
this complication of pregnancy (9). At all gestational ages, and 
especially the very early ages, inflammation in the pregnant uterus, 
either due to infectious or non-infectious causes, is commonly 
associated with preterm deliveries (10). For cases where the age is 
closer to term, a major concern is medical intervention which at 
times may not be medically indicated. In other cases, the delivery 
may be expedited to prevent stillbirth or maternal morbidity, 
such as for preeclampsia, fetal growth restriction, or diabetes. In 
half of all cases of PTB, labor commences spontaneously for no 
known reason or the membranes rupture unexpectedly leading 
later to the birth. These various phenotypes are diverse and poorly 
classified, reflecting our incomplete understanding of their vari-
ous causal pathways and mechanisms.
The impetus to discover strategies by which PTB rates may be 
lowered has been driven at least in part by advances in neonatal 
care resulting in more babies surviving at lower gestational ages 
at birth, but often at high cost in human and financial terms. 
Starting in the 1960s, much attention was given to developing and 
refining tocolytic drugs, which are therapeutic agents aiming to 
inhibit uterine contractions and hence prevent early birth. These 
drugs may have some usefulness in delaying PTB by hours or a 
few days, but do not extend pregnancies to gestational ages that 
will lower the rate of PTB (11).
SUCCeSS SO FAR
There has been success in lowering PTB rates to some extent in 
some environments (5). In USA, the rising rates of non-medically 
indicated late preterm and early-term birth, peaking in 2007, 
led to the launch of several quality assurance programs aiming 
to prevent unnecessary early births (6). These programs have 
resulted in successfully lowering the rates of late PTB in those 
hospitals and regions that were targeted. In part, as a result of 
these programs, the rate of PTB in USA fell for 8 years in a row, 
but has now been reported in late 2016 to have increased again 
from 9.57 to 9.63% (12).
The first whole of population and whole of geographic region 
PTB prevention initiative was recently reported for the state of 
Western Australia (13). Six strategies were applied: administra-
tion of progesterone based on prior history of a PTB or the find-
ing of a shortened cervix measured routinely in mid-pregnancy 
on ultrasound examination, appropriate use of cervical cerclage, 
avoidance of non-medically indicated induction of labor or 
Cesarean section, avoidance of exposure to cigarette smoke, 
judicious use of fertility treatments, and a dedicated PTB pre-
vention clinic at the state’s sole tertiary level perinatal center 
for referral of cases at highest risk. Implementation involved a 
state-wide outreach program aiming to ensure that all obstetri-
cians, general practitioners, midwives, and ultrasound imaging 
specialists had training and expertise in the various aspects of 
the program. Women and their families were made aware of 
the strategies through print and social media. The program 
overall was badged as thewholeninemonths™. After the first 
full 12 months of implementation, the state-wide rate of PTB 
had reduced by 7.6% when compared with the years prior to 
initiation. Statistical modeling estimated that approximately 
200 preterm births had been prevented with avoidance of 
more than 40 in the <32-week gestational age group. Analysis 
by run charts indicated the rate of late PTB had decreased 
rapidly, suggesting an effect of educational programs aiming 
to discourage practitioners and women from unnecessary early 
intervention. A more delayed effect was observed in reducing 
births in the 28–31 week category, possibly reflecting use of 
cervix length screening, administration of progesterone, and 
surgical cerclage. The benefits extended across the gestational 
age spectrum from 28–31 weeks onward, although any effect at 
ages before that time was not statistically significant possibly 
due to low numbers. An even greater effect in reducing the 
overall PTB rate was observed within the tertiary level center 
itself, where awareness among practitioners and pregnant 
women may have been greater. Together, these results indicate 
that a comprehensive and multi-faceted geographic-based PTB 
prevention program in a relatively high resource setting can 
significantly reduce the rate of PTB using existing knowledge, 
with an effect of 7–8%.
The magnitude of this reduction in PTB rates recently observed 
in the Western Australian program is generally consistent with 
a previous estimate of the effect that could result from effective 
implementation of known strategies. In an analysis of the poten-
tial reduction in preterm births for countries with a very high 
human development index conducted by the Boston Consulting 
Group and published in 2013, it was estimated conservatively that 
the combined impact of implementing known strategies may be a 
reduction in rate of 5% (14).
We are now left with two great challenges. First is to explore 
how the array of known strategies can be applied effectively across 
other population groups. Second is to discover new strategies by 
which our modest success so far can be expanded. One possibility 
may be to apply the principles of Precision Public Health to the 
field of PTB prevention.
PReCiSiON PUBLiC HeALTH
Precision public health has arisen from the emerging field of 
precision medicine (15, 16). Contemporary clinical practice is 
built upon practice guidelines that are developed and refined 
by the principles of evidence-based medicine. Typically, such 
guidelines are applied to individuals with specified symptoms 
or signs or abnormalities in laboratory or imaging tests. There 
is much greater potential benefit if the case selection could be 
refined by tests predicting that a given treatment is likely to be 
most effective for a given individual with a given disease. As an 
example, the drug crizotinib has been shown to be much more 
effective for the treatment of non-small cell lung cancer if the 
patient has a particular chromosomal translocation involving the 
gene encoding ALK that drives tumor growth (17).
But there is far more potential to the concept of precision 
medicine than just “drugs, genes, and disease.” Rather than 
merely targeting individuals by identifying specific phenotypic 
or genotypic characteristics, a population approach is possibly 
the next logical step. Identifying population groups rather than 
just individuals may yield great benefits. With such an approach, 
FiGURe 1 | The application of precision population health principles to preterm birth (PTB) prevention. Primary population screening using a number of 
known epidemiological, social, and obstetric factors can identify women with increased risk of PTB but has poor predictive value. In the three examples illustrated, 
women identified with a specific risk factor are then further evaluated using precision screening, aided by the application of various “omic” technologies, to identify 
those at greater risk of PTB associated with specific etiologies. This precision risk profile is then used to target treatment and prevention strategies to those who are 
most likely to benefit. Women who are unlikely to benefit from treatment are also identified through this process. This approach will enhance efficacy, reduce 
unnecessary interventions, and make optimal use of clinical resources. Abbreviations: BMI, body mass index; BV, bacterial vaginosis; Cx, cervix; fFN, fetal 
fibronectin; PTB, preterm birth.
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development of precision public health may enable us to benefit 
the right population at the right time.
Using a population-level approach, the massive amount of 
data currently being generated from multiple sources could be 
harnessed for the purpose. Such data collection systems include 
genomic, transcriptomic and microbiome analysis, and lifestyle 
characteristics measurable by electronic machines worn or car-
ried by individuals. We also need to expand our capabilities in 
harnessing data that describe the social and environmental deter-
minants of our health. Clinicians have traditionally incorporated 
informal information on these determinants into their clinical 
decision-making, but never before have we had access to data that 
can provide an accurate description of such factors. We are no 
longer lacking in information. Our challenge is how to embrace 
these massive data sources and use the information to identify the 
right populations at the right time for the right treatment.
The purpose of this article is to explore ways in which the 
principles of precision public health could be applied to the field 
of PTB prevention. Different scenarios will be discussed covering 
some of the strategies that are currently being employed for this 
task, and we will explore some of the possible avenues by which 
the principles of precision public health may be incorporated. 
The concept and examples are illustrated diagrammatically in 
Figure 1.
NATiONAL DiFFeReNCeS, POPULATiONS 
iN TRANSiTiON AND HeALTH 
iNeQUALiTieS
There are many lessons to be learnt from studying the rates of 
PTB in various nations, how these rates change with time, and 
the effects of migration.
The PTB rate varies markedly between different countries. In 
a study of national estimates of PTB rates in 2010 and published 
in 2013, rates ranged from 5.3 per 100 live births in Latvia to 14.7 
per 100 live births in Cyprus (14). Northern European countries 
had very low rates ranging from 5.5 per 100 live births in Finland 
to 5.9 in Sweden and 6.0 in Norway. More southern European 
nations had slightly higher rates with 6.5 in Italy, 6.7 in France, 
and 8.0 in the Netherlands. In contrast, the rate in USA was 12.0 
per 100 live births.
Different migrant subgroups have different reproductive 
responses to migration (18). Black and Hispanic migrant women 
are less likely to deliver preterm than US-born Blacks and Hispanics, 
but the effect does not extend to White and Asian migrants. The 
duration of residence in the new country also contributes greatly. 
In a study of migrants to Canada, recent immigrants of less than 
5 years had a lower risk of PTB than non-immigrants; but after 
15 years or more, the protective effect was reversed and a higher 
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risk of PTB than in non-immigrants was observed. No such 
effect was found on birth weight relative to gestational age (19). 
Chinese women living in Jiangsu Province were found to have a 
much lower rate of PTB than China-born women living in Hong 
Kong and Western Australia (20). In China-born women living 
in Western Australia, the ability to be fluent in English and no 
longer need a translator was associated with a doubling in risk of 
the pregnancy ending preterm, suggesting that environment was 
overriding genetics in terms of PTB risk.
The wide variation in PTB rates between countries, and the 
changes observed with migration, provides strong evidence 
for environmental contributors and clues to the magnitude 
of effect that may be amenable to change in any prevention 
strategy. But what factors associated with migration are operat-
ing to decrease and increase PTB rates, and how might this 
information be exploited in a precision public health approach? 
Large amounts of data are now available in various govern-
ment agencies on people as they either reside in their country 
of origin or migrate. Details are also available on when they 
moved, at what age, and the circumstances under which they 
re-located. It seems likely that harnessing these databases would 
add greatly to our ability to identify women at risk of PTB and 
enable us to devise public health strategies that may mitigate 
this risk. Much of the information of course is collected for 
other purposes and the challenge now is to bridge the gap with 
the many government and private agencies that generate and 
control such data bases.
Geographic information systems (GIS) employ sophisticated 
software and hardware platforms to analyze and collate data on 
geospatial distribution of disease incidence, risks, and health 
outcomes (21–23). While the technology and its applications are 
in their infancy, studies have shown that GIS is a useful modality 
for guiding public health policy and gaining high precision data 
on population risks, comorbidities, changes in incidence rates, 
effectiveness of treatment programs, and socioeconomic factors 
associated with risk (24–26). As far as we are aware, this approach 
has not yet been explored for PTB prevention, but there are clearly 
opportunities to be exploited here for improved and innovative 
public health PTB prevention initiatives.
A variety of population-based PTB prevention programs 
are now underway, each targeting the needs of their own 
communities and aiming to overcome deficiencies that may 
be contributing to high rates of early birth. In USA, several 
programs have been launched aiming to overcome health 
inequalities. Much of this work has resulted from awareness 
of the very different rates of PTB among the various racial 
groups. In 2014, the rates ranged from 13.2% in non-Hispanic 
Black women through to 9.4% in Hispanics and 8.9% in non-
Hispanic Whites (27, 28).
In Kentucky, one such program named “Healthy Babies Are 
Worth The Wait” has focused on improving access to antenatal 
care by incorporating a range of modifiable factors including 
group care (6, 28). When compared with surrounding states, 
there has been evidence of improved rates of PTB.
Central to the high rates of PTB in women of poor socio-
economic and educational standards may be factors operating 
in their neighborhoods and lifestyles that produce chronic 
stress and a sense of alienation (6, 28). Living in environments 
of high crime rates, low wages, lack of employment opportuni-
ties, sub-standard services, and feeling excluded from society is 
associated with higher rates of PTB. Understanding the pathways 
by which these multiple factors lead to pregnancy complications 
and other adverse health outcomes will require a much broader 
view of an individual’s life than we have previously appreciated. 
Tackling these considerable challenges may be assisted by access 
to large data bases and an understanding of the importance of the 
entire life-course in health and disease, as well as gaining a better 
understanding of how inter-generational effects, such as history 
of slavery and disempowerment may leave enduring effects on 
people and their communities. Much work is left to be done, but 
applying the principles of Precision public health may enable 
progress that has so far remained elusive.
TOBACCO eXPOSURe AND PTB
Exposure to tobacco products, either directly or from environ-
mental sources, is recognized as a significant threat to human 
health and a significant cause of PTB. The importance of con-
trolling tobacco exposure during pregnancy is underscored by 
tobacco exposure being designated the single largest preventable 
risk factor for non-communicable human disease (29). Data 
published by the World Health Organization show that some 6% 
of all female and 12% of all male deaths are attributable to tobacco 
use (30). By 2020, the WHO projects that 7.5 million people will 
die from direct and indirect exposure to tobacco smoke (30). 
Data drawn from populations in the United States, Denmark, 
Sweden, and Canada (i.e., broadly high-income economies) sug-
gest that fewer than 50% of women who smoke cease smoking 
during pregnancy; Swedish data from 2000 suggest that 13% of 
women in that country smoked during pregnancy, with smoking 
persistence more likely in those women with a lower level of edu-
cational attainment (31). Accordingly, tobacco control and PTB 
prevention constitute tightly intertwined and hugely important 
global public health challenges.
Tobacco Use and Pregnancy
The greatly elevated risks of lung cancer, chronic respiratory 
disease, and cardiovascular disease [71%, 42%, and 10% of 
total incidence, respectively (30)] associated with smoking are 
well appreciated by both the medical community and the gen-
eral public; however, the risk of adverse pregnancy outcomes 
associated with maternal tobacco exposure, and the benefits of 
smoking cessation prior to or early in pregnancy, are equally 
profound (32–34). Although protective for preeclampsia (35, 
36), smoking during pregnancy is causally associated with fetal 
growth restriction, placental abruption (37), PTB (38, 39), and 
sudden infant death syndrome (40). At least one-third of all cases 
of fetal growth restriction in developed countries is attributable 
to the effects of maternal tobacco use (41). There are also data to 
suggest that fetal exposure to many chemicals in tobacco smoke 
is associated with a host of childhood developmental abnormali-
ties, including subnormal weight gain (42) and neuro-behavioral 
disorders, such as attention deficit hyperactivity disorder and 
deficits in auditory and cognitive ability (43).
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A 1990 report by the US Surgeon General concluded that 
“women who stop smoking before pregnancy or during the first 
3–4 months of pregnancy reduce their risk of having a low birth 
weight baby to that of a woman who never smoked” (44). Perhaps, 
the most important element of this report, in keeping with semi-
nal studies into smoking-related mortality among UK doctors by 
Doll and colleagues, is that the adverse effects of tobacco expo-
sure on pregnancy are not immutable and can be reduced or even 
entirely abrogated by timely smoking cessation (45). Numerous 
subsequent studies, both experimental (46) and epidemiological 
(47–49), have demonstrated both the significant potential harm 
to pregnancy and the developing fetus caused by maternal tobacco 
smoke exposure and, promisingly, the profound benefits to both 
that may be gained from effective tobacco control.
It is now well established that PTB is a complex syndrome, 
in many cases likely patient and/or population specific, and a 
syndrome for which very few preventative interventions exist (9). 
Of the limited armamentarium presently available to the medical 
and public health communities, tobacco control is among the 
most uniformly effective interventions. A meta-analysis of the 
effects of implementing smoke-free legislation in North America 
and Europe reported a statistically significant 10% reduction in 
PTB [1,366,862 cases; −10.4% (95% CI −18.8 to −2.0); p = 0.016] 
(48). Similar benefits have been reported in response to tobacco 
control measures adopted in Switzerland, with benefits to popu-
lation pregnancy health correlating with the extent of tobacco 
control achieved in a particular canton (50). Recent modeling 
by Levy and colleagues identified that a $2/pack cost increase in 
cigarette excise tax, combined with cessation programs, health 
warnings, and public smoking bans would deliver a 33.5% reduc-
tion in smoking prevalence among US women aged 15–49 by 
2065; relative to maintaining the status quo, such policy measures 
would deliver 227,300 fewer (132,600–302,300) low birth weight 
infants and 351,000 (137,100–501,300) fewer preterm births over 
the same period (51).
Controlling Tobacco exposure to Prevent 
PTB via Precision Public Health:  
A Nuanced, Multilevel Approach
Reducing the adverse impact of tobacco exposure on pregnancy 
outcomes likely requires a combination of national-level initia-
tives, supported by complementary, culturally, and contextually 
appropriate programs targeted at specific communities and 
individual patients. Given the substantial body of data linking 
tobacco exposure to human disease generally (29, 45), preventive 
programs based around national public education and legislative 
control (52) (high levels of tobacco excise tax, comprehensive 
advertising bans, prohibition of tobacco use in public places, pub-
lic education campaigns) are clearly warranted and, when well-
executed, demonstrate marked reductions in population-level 
tobacco use coincident with significant reductions in population 
PTB rates (47, 48, 50). Such programs, targeting both males and 
females, are important as there is very good evidence that both 
direct maternal tobacco use and environmental exposure in the 
home, workplace, or public transport, convey sizeable risks to 
pregnancy health. In addition to the risks of second-hand smoke, 
data from the Generation R study in the Netherlands also suggest 
that, in a number of communities, partner smoking is associated 
with smoking during pregnancy (53).
Unfortunately, countries employing comprehensive, multi-
faceted tobacco control measures at a national level remain in the 
minority. Many of the countries with sub-optimal tobacco control 
measures are the same low- and middle-income countries that are 
home to 80% of the world’s smokers (31) and report some of the 
highest rates of PTB in the world (2, 4, 54). Even in countries with 
effective national-level controls, there are marked differences 
in the effectiveness of national-level tobacco control measures 
between communities (53, 55), seemingly contingent on a host 
of socioeconomic factors. In addition to determining maternal 
tobacco use history and environmental exposure (especially in the 
home), a precision public health approach to preventing tobacco-
associated PTB would likely require assessment of maternal and/
or community factors, including (but not limited to), ethnicity, 
education, poverty, the ability to access social support networks, 
and the ability to access health-care services.
Ethnicity should be accounted for when designing pregnancy 
smoking risk assessments and interventions. An analysis of 
smoking habits in the Netherlands as part of the Generation R 
study showed significant differences in smoking rates between 
women of Turkish (43.7%), Dutch (24.1%), and Moroccan (7.0%) 
ethnicities; moreover, women of Turkish and Moroccan ethnicity 
were more likely to continue smoking during pregnancy (72.0 
and 70.6%, respectively) than women of Dutch ethnicity (58.6%) 
(53). In South Australia, data collected during the 1990s revealed a 
marked difference in smoking rates between Aboriginal and non-
Aboriginal women (57.8 vs. 24.0%) at their first antenatal visit 
(56). A similar disparity is evident in more recent data collected 
in Queensland between 2005 and 2006, with 54% of Indigenous 
and 19% of non-Indigenous women reporting smoking during 
pregnancy (55). In the study, adjusted pregnancy outcomes in 
non-smoking Indigenous and non-Indigenous women were 
almost equivalent, underscoring the profound impact of smok-
ing on pregnancy and the potential benefits to be gained from 
effective cessation support (55).
A mother’s level of educational attainment and financial situ-
ation are known to be important predictors of peri-conceptual 
smoking habits and the ability to quit smoking once pregnancy 
is established (31, 57). Hibbs and colleagues undertook a cross-
sectional study of PTB rates among women residing in low-
income urban areas in Illinois; the findings of this study showed 
that impoverished African-American women who smoked 
exhibited a pattern of “weathering” with advanced maternal 
age associated with increased rate of PTB [25.2% among 30- to 
35-year-old women vs. 17.9% for teenagers; RR = 1.5 (1.1–2.0)]. 
Interestingly, the authors reported that impoverished White 
mothers (irrespective of smoking status) and non-smoking 
African-American mothers did not exhibit a similar pattern of 
increased rates of PTB with increasing maternal age. The authors 
concluded that their findings underscore the “potential public 
health benefit of cigarette smoking cessation programs aimed 
at the most economically disadvantaged African-American 
women” (57).
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The level of social support and community integration avail-
able to a mother is believed to play an important role in pregnancy 
outcomes and may impact behaviors, such as smoking, during 
pregnancy. Indeed, smoking has been reported as one means by 
which women cope with stress in adverse domestic situations, 
including poverty and disadvantage. In a Turkish study, Ergin 
et  al. reported that young age (<20), low education level, and 
migrant status were associated with smoking during pregnancy 
(58). Similarly, in a German cohort, Elsenbruch and colleagues 
reported that a lack of social support in pregnancy is a key 
risk-factor for adverse outcomes and that women categorized as 
having low social support during pregnancy were far more likely 
(34 vs. 17%) to self-report smoking during the first trimester of 
pregnancy than women categorized as having high levels of social 
support (59). These findings mirror earlier findings summarized 
by Dejin-Karlsson and colleagues, wherein women with strong 
social support networks are more successful at successfully quit-
ting smoking, and that an absence of support networks is one 
reason why some pregnant women continue to smoke (60).
Given the relationships between PTB and inadequate antena-
tal care, economic disadvantage, low-educational attainment, and 
ethnicity, a number of investigators have recommended the use 
of community outreach programs or clinics involving multiple 
disciplines sensitive to the particular needs of the community 
in question (61). Interventions based on nuanced patient risk 
assessments that consider individual and community-level 
factors may thus benefit attempts to reduce the rate of tobacco-
associated PTB, and should be considered in any precision public 
health approach to PTB prevention. Risk assessments could be 
used to design and deliver targeted, culturally and contextually 
appropriate interventions at community (i.e., comprehensive anti-
smoking programs and cessation support through community, 
religious, sporting and cultural groups, supported by community 
leaders) and individual (psychotherapy and pharmacotherapy for 
smoking cessation, midwife outreach programs, access to social 
support and mental health services, assisted transport to access 
health-care services) levels.
POPULATiON-BASeD CeRviX LeNGTH 
SCReeNiNG
While there are many pathways leading to PTB, some cases 
may be predicted by measurement of the length of the cervix 
in mid-pregnancy (62–64). This measurement may be done as 
a component of the standard mid-pregnancy morphology scan 
typically conducted between 18 and 24 weeks gestation.
If the cervix appears shortened on trans-abdominal scan, a 
transvaginal scan is then recommended. For pregnancies where 
the risk of PTB is perceived to be increased, the standard of 
practice is generally to proceed to transvaginal scan to measure 
the cervix length.
The finding of a shortened cervix in mid-pregnancy is pre-
dictive of PTB, and there are treatments that reduce that risk, 
at least for singleton pregnancies. Administration of natural 
progesterone vaginally as a single evening dose has been shown 
to nearly halve the risk of PTB in such circumstances. This benefit 
has been shown in large randomized controlled trials and also by 
meta-analysis of individual patient data (65–67).
So, we now have strong evidence that the risk of PTB can be 
reduced dramatically, perhaps by about half, in women found 
in mid-pregnancy to have a short cervix and then using that 
information to prescribe natural vaginal progesterone which is a 
relatively simple and safe treatment. Should the test and its sub-
sequent treatment be applied to the entire population of pregnant 
women?
In the largest American randomized controlled trial, Hassan 
and colleagues screened 32,091 women by transvaginal scan to 
identify 733 with a cervix shortened and measuring between 10 
and 20  mm (65). Two hundred thirty-six were randomized to 
the vaginal progesterone treatment group, 229 to placebo and 
268 declined to participate further. The effect was to nearly halve 
the rate of early PTB in those found to be at risk; the number of 
births <33 weeks was 21 cases in the treatment group (8.9%) and 
36 cases in the placebo group (16.1%). Thus, if the findings of 
this trial were to be replicated in general clinical practice with no 
women receiving a placebo and all women participating in the 
treatment, then screening 32,000 women would identify 2.3% of 
women requiring treatment and would result in the prevention of 
47 cases of births <33 weeks (5).
More recently, the largest randomized controlled trial to have 
been conducted so far, based in UK, observed a non-significant 
effect on three primary outcomes—fetal death or birth <34 weeks 
gestation, a composite of neonatal outcomes, and a standardized 
cognitive score at 2 years of age (68). There were multiple entry 
criteria and the treatment consisted of vaginal progesterone from 
22–24 to 34  weeks. When the data from the various trials are 
included in an updated meta-analysis, the beneficial effect of vagi-
nal progesterone treatment for prevention of PTB in women with 
a singleton pregnancy and shortened cervix in mid-pregnancy 
remains statistically significant (67).
A cohort study assessing the introduction of routine cervix 
length screening in mid-pregnancy at a single tertiary level center 
in Chicago, IL, USA, observed a reduction in preterm births 
that appeared to be spread across the preterm gestational age 
spectrum when compared with outcomes prior to introduction 
of the program (69). The reductions were from 6.7 to 6.0% for 
births <37 weeks, 1.9 to 1.7% for <34 weeks, and 1.1 to 1.0% for 
<32 weeks gestation. In this population, the frequency of cervix 
length less than 25 mm in mid-pregnancy was 0.89%.
But would it be cost-effective to introduce this protocol into 
clinical practice across the entire population? In a USA-based 
decision analysis model of a single cervix length measurement 
in mid-pregnancy compared with no such measurement, with 
treatment with vaginal progesterone if the cervix were found to be 
shortened, it was estimated the program would save $12 million/
year and gain 424 quality-adjusted life years (70).
A more recent USA-based analysis asked if risk-based screen-
ing would be more or less effective than universal screening of all 
pregnancies (71). Results of the decision analytic model indicated 
that both risk-based and universal screening would be more 
cost-effective than no screening. Of the two approaches, universal 
screening of cervix length measurement of all pregnancies was 
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superior to risk-based screening and would result in a higher 
cost-effectiveness ratio.
Despite the evidence presented above, there remain as many 
unknowns as knowns. What is the prevalence of shortened cervix 
in mid-pregnancy in the various populations of the world? Even 
within the USA there is considerable variation, ranging from 
0.89% <25 mm in the Chicago study (69) to 2.3% <20 mm in 
the multicentered trial reported by Hassan and colleagues (65). 
Regions such as northern Europe where the rate of PTB is much 
lower are likely to have even lower prevalence of shortened cervix 
in mid-pregnancy. Further, we have few data describing the phe-
notypic and genotypic variables that influence mid-pregnancy 
cervix length and the response to treatment, and we have little 
understanding how to monitor and manage cases undergoing 
treatment and the drivers of treatment success and failure. This 
is a key issue in the context of precision public health (Figure 1). 
Interestingly, a small USA study found that progesterone and 
cerclage therapies were only effective in women with biomarkers 
of inflammation in the amniotic fluid and that without inflamma-
tion the risk of PTB was actually increased (72). This preliminary 
evidence suggests that the inclusion of additional screening 
parameters, such as inflammation, might improve precision and 
response to targeted therapies.
To achieve improvements in precision, we need to progress 
beyond case studies and randomized controlled trials. In the 
first instance, we need sound and reliable population-based 
data. Most high resource nations have perinatal collection sys-
tems collecting basic information on demographics, the birth, 
and the newborn. To fully understand and maximize the benefit 
from mid-pregnancy cervix length measurement and treat-
ment, such data collection systems will require much greater 
complexity and capability. The expansion will be complicated 
by the fact that many health-care systems are fragmented, with 
antenatal investigations and treatments often being dislocated 
from hospital-based birthing processes. Prevention of PTB is of 
great benefit to individuals and the community, and develop-
ment of cost-effective models of health-care delivery using this 
intervention should be entirely feasible. At this time, it would 
seem reasonable to expect that the most effective solution will 
come from population-based screening, but followed by further 
precision analysis to best understand the most appropriate 
treatment for each case and the manner by which that treatment 
should then be monitored for effectiveness.
AvOiDANCe OF NON-MeDiCALLY 
iNDiCATeD LATe PReTeRM AND eARLY-
TeRM BiRTH
The rates of late preterm, and early-term, birth have been increas-
ing over recent decades in many countries (73, 74). These trends 
have been underpinned by a general assumption held by many 
people that birth close to term will not be associated with any 
enduring compromise for the offspring. A wealth of data, from 
multiple societies, now suggest otherwise.
Being born late preterm, defined as birth between 34 and 
36 weeks and 6 days gestation, places the infant at risk of neonatal 
and childhood consequences (75). For the neonate, complica-
tions may include the need to be admitted to a neonatal intensive 
special care unit, and special support to maintain respiratory 
function, temperature control, prevention of infection, and 
maintenance of normal glucose levels, and much more (75, 76). 
For the child, there are increased risks of death, re-admission 
to hospital, cerebral palsy, developmental delay, and behavioral 
and learning problems at school age (77, 78). In recent years, the 
findings of potential compromise from prematurity for the child 
have been extended to birth in the early-term period, ranging 
from 37 weeks and 0 days to 38 weeks and 6 days.
For those cases in which early birth is required for maternal or 
fetal reasons, the benefits may outweigh any risks of prematurity. 
But, we now have strong evidence that there are many cases where 
such a benefit is not the case, and steps need to be taken to ensure 
that any elective early births can be fully justified.
Population-based study of the factors involved in rising rates 
of early births has shown clear demographic differences (2, 14, 
79). In a USA study of early births between 1992 and 2002, the 
major increase in rate was observed in non-Hispanic White births 
(80). During the decade of study, rates of early births in Hispanic 
and Black women had remained relatively constant. The factors 
underpinning these observations are uncertain, but suggest that 
socioeconomic factors are involved and that both medical and 
patient contributions need to be considered.
Reducing the rate of early intervention is particularly chal-
lenging, but progress has been made by some health-care systems. 
In a study of 27 health-care facilities in USA, each organization 
was invited to choose one of three protocols to reduce their rate 
of non-medically indicated late preterm and early-term birth 
(81). The options ranged from just education of staff through to 
complete prohibition of early birth. The gestational age below 
which non-medically indicated birth was to be discouraged 
was 39 completed weeks. Outcome data revealed that the most 
interventionist protocols produced the greatest benefit, with sig-
nificant reductions in early birth rates and admissions to neonatal 
intensive care units. The still birth rate did not change during the 
time of the study. Education alone did not improve outcomes, but 
of importance, the program only involved the medical staff and 
did not include education of other health-care practitioners or the 
patients themselves.
At a national level, there has been considerable public advo-
cacy across USA led by the March of Dimes though a campaign 
called “Healthy Babies are Worth the Wait,” coupled with quality 
improvement initiatives (6). These programs have been aimed 
primarily at health-care providers and pregnant women to dis-
courage unnecessary early intervention. The results of these and 
other programs suggest that the rates of non-medically indicated 
late preterm and early-term birth rates can be reduced, but there 
are many confounding factors.
First, the effect is entirely dependent on the extent to which 
unnecessary early intervention is prevalent in a particular health-
care environment. Further, it is clear that individual health-care 
practitioners and their pregnant patients actively choose to 
make such decisions. Understanding when preventative policies 
should be introduced requires detailed understanding of not 
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just health-care outcomes but also the practices of individual 
practitioners and the attitudes of women and families who access 
such care.
Second, are the health-care workforce implications of discour-
aging elective birth before 39 weeks gestation. Such a policy will 
inevitably increase the number of cases of spontaneous labor, 
and there are clear implications for the work–life balance of busy 
practitioners, especially those in solo or small group practices. In 
a secondary analysis of a randomized controlled trial in Denmark 
comparing planned elective Cesarean births at 38 or 39 weeks ges-
tation, delaying the surgery by 1 week resulted in a 60% increase in 
unscheduled Cesarean sections and a 70% increase in births out-
of-hours (82). Imposing health-care guidelines that potentially 
compromise the daily activities of practitioners and hospitals 
requires considerable justification and a thorough understanding 
of the issues involved in each health-care environment.
Third, is the potential for stillbirth or fetal compromise by 
delaying birth. There is no convincing evidence at a population 
level that earlier delivery is associated with lesser rates of stillbirth 
but it is logical to assume that a background risk of fetal death 
must remain present by continuing the pregnancy, even in the 
absence of any known risk factors. Any such risk would need 
to be weighed against any potential risk of death or morbidity 
resulting from late preterm or early-term birth. Reassuringly, 
the American trial of three management options in 27 hospitals 
significantly reduced early birth rates and there was no evidence 
of any increase in risk to the child. In the Danish RCT of elective 
Cesarean delivery at 38 or 39 weeks gestation, there was a small 
reduction in rate of delivery to the NICU in the delayed delivery 
group, but no other signs of danger (82, 83).
It is clear, therefore, that the challenge to prevent non-medically 
indicated late preterm/early-term births is scientifically justified, 
but confounded by regional differences, possible benefits and 
risks to the child by continuing the pregnancy, and potential 
adverse effects on the practitioners and their health-care facili-
ties. For each health-care environment, detailed and ongoing data 
availability and analysis are vital if preventative strategies are to 
be introduced and be maintained. So far, in USA and Western 
Australia, there has been success in lowering the rates of late pre-
term/early-term births, but continuing success and translation 
into other environments where the baseline PTB rates are already 
lower may be more challenging. The principles of precision public 
health may offer the solution to this major problem. By applying 
precision analysis using factors such as genetic predisposition, 
prior history, and lifestyle variables, we may better understand 
which pregnancies can safely be left until after 39 weeks gestation 
and which cases require earlier intervention.
PReveNTiON OF iNFeCTiON-DRiveN PTB
It is well established that microbial infection of the extra-placental 
membranes, amniotic cavity, and fetus is an important driver of 
PTB, particularly in the deliveries at the earliest gestational ages (9, 
84, 85). Animal models and clinical studies demonstrate a causal 
relationship between infection and PTB, while the immune-
pathophysiological pathways responsible for triggering preterm 
labor in response to infection have been studied, replicated and 
characterized in a variety of models (86–88). The most common 
pathway via which bacteria trigger PTB is the so-called ascending 
infection route: microorganisms residing in cervico-vaginal fluid 
in pregnancy ascend through the cervical barrier and colonize 
the fetal membranes, passing through in some cases to colonize 
the amniotic fluid and from there infect the fetus (86, 89). The 
severity of the infection and the ensuing inflammatory response 
determines, to a large part, the obstetric and neonatal outcomes, 
including the timing and onset of preterm labor, the effectiveness 
of tocolytic therapy, and the risk of serious neonatal morbidities.
While the majority of preterm deliveries occur in the 32- to 
36-week period, the costs and risks of serious perinatal morbidi-
ties are highest in deliveries <32-week gestation, the majority of 
which are infection-associated (9, 84, 85). Hence, preventing PTB 
as a result of intrauterine infection has the largest potential gains 
in terms of reducing major morbidity and death and reducing 
perinatal and lifetime health-care costs (90, 91).
Unfortunately, identifying women at risk of infection-driven 
PTB and treating them to prevent the infection is challenging, 
both from an individual patient and public health perspective 
(92–94). Gestational tissues exposed at different times in preg-
nancy to different bacteria exhibit variable immune responses 
depending on dose, duration, distribution, maternal and fetal 
genetics, ethnicity, lifestyle, and anatomical factors (such as 
previous cervical surgery). This level of heterogeneity makes 
identification and risk prediction particularly difficult. There are 
several well-documented approaches which can identify women 
at increased risk of infection-related PTB, yet their prognostic 
value is generally too weak to alter clinical decision-making and 
treatment. Many of the trials of prophylactic antibiotic therapy 
given to pregnant women to prevent PTB have failed to employ 
robust inclusion criteria or delivered poorly effective antibiotic 
regimens (95, 96). Identifying women who will benefit from treat-
ment is a key requirement for primary prevention: prescribing 
antibiotics to large numbers of women in pregnancy in order to 
prevent PTB in a small percentage of recipients is not justifiable in 
light of the emerging recognition of the potential developmental 
effects of disrupting the maternal and neonatal microbiomes with 
antibiotics in pregnancy (97–100).
To date, primary prevention research has focused on identify-
ing and treating women with abnormal vaginal microbiota in 
early pregnancy prior to the onset of preterm labor (101, 102). 
This strategy is based on the assumption that women with vaginal 
dysbiosis have increased risk of ascending infection and that 
antibiotic treatment will eradicate the pathogens, prevent infec-
tion, and thus prevent PTB. The odds ratio of women delivering 
preterm with bacterial vaginosis (BV) or aerobic vaginitis (AV) is 
approximately 2–7, and even higher if diagnosed before 16-week 
gestation (103–105). The presence of Ureaplasma in the vagina is 
also associated with an approximately twofold increased risk of 
PTB (106–108). However, due to its high prevalence in pregnant 
women (~50%) (109), detection of Ureaplasma alone is not 
sufficiently diagnostic to warrant prophylactic treatment. The 
prognostic significance of the presence of specific Ureaplasma 
serovars is currently under investigation (109).
A large number of trials have employed standard micro-
biological or clinical approaches to identify women with vaginal 
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dysbiosis and treated them with antibiotics (with or without 
probiotics) to prevent PTB (84, 110, 111). Many of these studies 
failed to significantly lower the rate of PTB (111–114), although a 
few studies employing clindamycin treatment before 22 weeks of 
pregnancy have shown significant maternal and neonatal benefits 
(95, 96). The negative findings are, in part, due to lack of effec-
tive antimicrobial interventions (95) and the failure to treat the 
dysbiosis or address recurrence (115–117). However, the major 
impediment to therapeutic progress is the poor prognostic preci-
sion of current identification methods. Most women with vaginal 
dysbiosis or urogenital tract pathogens do not deliver preterm, 
and our ability to identify those at sufficiently high risk to warrant 
treatment (OR > 10) is poor (102). Primary prevention studies 
have focused on defining clinical vaginal microbial disorders 
and recruiting patients based on these definitions, rather than 
identifying subgroups of women who are at particularly high 
risk of delivering preterm as a result of microbial profile and/
or other risk factors and targeting them for appropriate and 
effective treatment. Currently, although rapid molecular tests for 
diagnosing BV and AV are being developed (118, 119), we lack 
an accurate, rapid, and affordable test to identify women at high 
risk of infection-related PTB (120, 121).
Nevertheless, despite these uncertainties and qualifications, 
there is encouraging evidence that public health screening 
for BV or other forms of abnormal vaginal microbiota using 
traditional techniques can be an effective primary prevention 
strategy in reducing PTB rates. A recently published Austrian 
study, implemented following the results of a randomized clini-
cal trial, retrospectively analyzed the pregnancy outcome data of 
over 17,000 women at high risk of PTB (based on general, family, 
and obstetric risk factors) across a 10-year timespan following 
introduction of a voluntary antenatal infection “screen and treat” 
program (122). All women received standard antenatal care; 
49.5% entered the screen and treat program, which consisted of 
testing of vaginal swabs at 10- to 16-week gestation for detection 
of BV and presence of Candida spp. or Trichomonas vaginalis, 
followed by antimicrobial treatment with either clindamycin, 
clotrimazole, or metronidazole as appropriate. Recurrent infec-
tions were retreated and women with BV were given probiotics 
after treatment to prevent recurrence. Women in the treated group 
had a significantly lower rate of stillbirth (0.4 vs. 2.0%), miscar-
riage (0.5 vs. 1.4%), PTB <37  weeks (9.7 vs. 22.3%), and PTB 
<32 weeks gestation (1.9 vs. 8.3%). The effect of the program on 
the rates of early/extreme PTB was particularly impressive, with 
a more than 77% reduction observed; this is consistent with the 
known role of intrauterine infection in the majority of deliveries 
<32 weeks. The major weakness in this study is its retrospective, 
non-randomized design, although confounding is minimal and 
unlikely to alter the findings (122).
These data are similar to the achievements of an earlier public 
health program implemented in Germany in late 1997 (123). 
The program consisted of a free self-test vaginal pH kit offered 
to 2,722 women in obstetric care (>12-week gestation), with 
optional follow-up with obstetricians if the test was positive. 
Elevated vaginal fluid pH is a weak surrogate marker of BV and 
AV, typically associated with a lack of Lactobacillus spp. Treatment 
with antibiotics (clindamycin) was indicated if clinical symptoms 
of BV were present following obstetric examination. The program 
resulted in much lower rates of PTB <32 weeks in the women 
who participated (14% of the cohort) compared to women under 
the same care who did not engage in the pH testing program (0.3 
vs. 4.1%). Subsequently, a large prospective trial was conducted, 
enrolling 8,000 women in the state of Thuringia over a 6-month 
period. Women who self-tested their vaginal pH and sought 
medical treatment based on the result (8% of the cohort) had 
lower rates of PTB at <32 weeks (0.3 vs. 1.6%) and at <37 weeks 
of gestation (5.3 vs. 8.5%). After discontinuation of the program, 
PTB rates returned to historical levels in the state (123).
In order to obtain greater precision, we need to refine our 
ability to identify women at high risk of infection-driven PTB 
(OR  >  10) and target them with appropriate follow-up and 
treatment. Many of the bacteria found in the amniotic cavity of 
preterm deliveries are normal commensals of the urogenital tract 
(124, 125), so vaginal microbiological profiling alone is unlikely 
to have a high positive predictive value. It remains to be deter-
mined whether more refined and selective molecular techniques 
may help to improve diagnostic discrimination (109). It is likely 
that a combination of clinical risk factors (e.g., prior PTB, cervical 
imaging, and abnormality detection), high-resolution microbial 
profiling (possibly including bacterial strain identification), and 
immunological/inflammatory biomarker assessment will be 
needed, in combination with a highly effective antimicrobial 
regimen (97, 126), to enable a truly effective maternal “screen 
and treat” program to achieve the desired level of precision and 
effectiveness required for a primary prevention public health 
program (127–133).
“OMiCS” AND PReCiSiON PUBLiC 
HeALTH
identification of At-Risk individuals: 
Genomic Approach
The contribution of genomic variation to the etiology of PTB 
is thought to be in the order of 40% by twin and family studies 
(134). Women who were born preterm, or who have close family 
members with a PTB, have a significantly higher risk of PTB. 
Rates of prematurity are influenced by ethnicity (135): studies 
have shown that the rates of PTB in African-Americans is sig-
nificantly higher than other racial groups in similar socioeco-
nomic settings, and that women married to African-American 
men have higher prevalence of PTB. Determining the precise 
nature of the genomic variants responsible for determining risk 
of PTB is hampered by the complex biology of preterm labor 
(135). From an evolutionary perspective, PTB is detrimental 
to the survival of the species, and there are multiple levels of 
redundancy in the biological process of labor initiation, which 
combine to reduce the incidence of PTB. The genetic basis of 
PTB is, therefore, unlikely to be monogenic. Rather, in all but 
the most extreme of phenotypes, multiple changes with gene 
pathways are required to overcome physiological redundancy 
and culminate in PTB.
The advantage of genome-based screening tests is that they 
may be applied prior to pregnancy and allow ample time to 
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initiate primary prevention, rather than attempting to slow or 
reverse the premature activation of parturition which leads to 
spontaneous preterm labor. Many gene-targeted analyses and 
genome-wide association studies (GWAS) have been carried out 
in an attempt to identify genetic variants associated with PTB 
(135). Sheikh et al., in a recent review of the literature, identified 
119 candidate genes with SNPs that had potential association 
with PTB in an evaluation of 92 different studies. Many studies 
have found association between SNPs in parturition-associated 
genes such as the progesterone receptor, oxytocin receptor, 
relaxin, the prostaglandin EP3 receptor, and the CRH receptor 1, 
although the level of risk associated with these polymorphisms 
is not sufficiently high to be useful clinically (136). Other 
target genes have yielded more promising SNPs, in particular 
heat-shock protein 47 (SERPINH1), which is involved in the 
maturation of collagen molecules and is enriched in African and 
African-American populations. Polymorphism in other tissue 
remodeling-related genes like metallopeptidase inhibitor-1 and 
2, COL1A2, COL5A2, and COL5A1 also significantly increase 
the risk of PTB (136). Overall, many of the SNPs significantly 
associated with PTB are related in some way to inflammation. 
Lack of replication and population-based heterogeneity remain 
major hurdles to be overcome.
Identification of combinations of multiple subtle genomic 
contributors are now feasible with advances in high-throughput 
genomic sequencing and bioinformatics. In a recent study of 
women with 2–3 generations of PTB using a meta-genomic, 
bi-clustering algorithm, Uzun et  al. (137) identified variations 
in 33 genes within five genetic pathways associated with altered 
PTB risk. Brubaker et  al. employed protein network analysis 
with tissue-specific gene expression data to identify functionally 
important candidate genes that would be overlooked by standard 
GWAS techniques. Their analysis identified significant sub-
networks and genes not previously associated with PTB, includ-
ing sub-networks associated with inflammation, muscle function, 
and ion channels (138). It is likely that extensions of such work 
will ultimately permit the characterization of an individual’s 
overall genomic risk of PTB as a screening test to identify those 
at risk, with the molecular consequences of the variation being 
used to guide preventive interventions.
Further advances are likely to originate from advances in the use 
of phenotypic data from rare genetic diseases to identify variants 
associated with common pathways shared by multiple disorders 
(139). To this end, the recently expanded Human Phenotype 
Ontology (www.http://human-phenotype-ontology.github.io) 
now contains 250,000 phenotypic annotations for over 10,000 rare 
and common diseases (140, 141), which can be used to examine 
the phenotypic overlap among common diseases with shared risk 
alleles or those linked by genomic location. Other databases and 
platforms have been developed to allow accurate assessment of 
the causal relationship between genetic variants and phenotype; 
these are becoming critical tools in clinical genetic diagnostics 
(140), for comparing phenotypes between patient cohorts (142) 
and for identifying new disease genes via the linkage of novel 
variants with well-defined phenotypes (141, 143). Application of 
such approaches to understanding the genetic causes of PTB and 
identifying populations at risk remains to be explored. However, 
several examples have already been identified. Insights may be 
expected from analyzing the links between PTB and Prader–Willi 
Syndrome (144, 145) or by studying Beckwith–Wiedemann 
Syndrome, which is associated with increased rates of PTB, gesta-
tional diabetes, polyhydramnios, and intrauterine bleeding (146). 
Advances in this area may lead to improved knowledge regarding 
genetic variants and pathways to PTB which can be exploited to 
enhance screening programs and develop and target interventions.
identification of At-Risk individuals: 
Transcriptomic Approach
Transcriptomic methods assess RNA in tissue and quantify the 
extent to which genes are functioning, rather than inferring vari-
ations in function related to variations in sequence. By examining 
expression of genes related to inflammation, for example, one can 
find evidence of inflammation prior to the development of clini-
cal manifestations. In PTB, a screening test could be developed 
to identify individuals with premature activation of parturition at 
a stage where treatment can reverse such activation prior to the 
tipping point to inevitable preterm labor (147).
As was the case for genomic methods, alterations in the tran-
scriptome in the lead up to PTB are likely to arise from multiple 
pathways. Heng et al. (148) described a method considering the 
expression levels of multiple genes from multiple pathways in 
maternal whole blood and their relationship to subsequent PTB. 
Applied to asymptomatic pregnant women at 28-week gestation 
and including clinical factors, their model predicted PTB with 
sensitivity of 65%, specificity of 88%, and false positive rate of 
11%; their birth cohort had been enriched, with a PTB rate of 31%. 
This method requires further validation in average-risk popula-
tions before being considered for clinical application. Alternative 
methods may employ samples other than maternal blood such as 
cervico-vaginal fluid, or analysis of micro RNAs and other related 
molecules which may give insights into placental pathologies and 
associated risk factors. With refinement, this approach could be 
useful in the identification of the woman heading toward PTB 
in whom interventions could arrest this course and allow safe 
delivery at term.
identification of At-Risk individuals: 
Proteomic Approach
As transcriptomics looks at the actual expression of genes rather 
than the sequence, proteomics goes a step further in examining 
the protein end products of gene function, giving insight into the 
physiological alterations related to gene sequence and expression. 
High-throughput proteomic assessments allow the identification 
of differentially produced proteins in association with clinically 
relevant phenotypes. From a PTB perspective, proteomic varia-
tion may herald early delivery prior to the development of clini-
cally apparent symptoms.
The most commonly employed protein assessment is fetal 
fibronectin in women who present with symptoms suggestive of 
preterm labor. This protein is found in greater quantities in the 
cervico-vaginal fluid in women who will deliver preterm than 
in those women whose pregnancy will continue to term (149). 
Quantitative or qualitative assessment of fetal fibronectin levels 
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permit the rationalization of therapies aimed at delaying delivery 
or reducing the adverse sequelae of prematurity.
A natural extension of the use of fetal fibronectin testing to 
stratify risk of PTB in symptomatic women is its application to 
asymptomatic women. To date, there is little evidence to support 
the adoption of such screening into routine clinical practice 
in low-risk pregnant women (150). It may have greater utility 
in the screening of women with other established risk factors 
(151–153).
Kim et al. (154) assessed the utility of amniotic fluid MMP-8 
as a screening test for subsequent PTB in women undergoing 
diagnostic amniocentesis in the mid-trimester. The test was 
highly specific (100%) for subsequent PTB, albeit with relatively 
low sensitivity (42%). The major limitation of this approach is 
the invasive nature of the test which is unlikely to be acceptable 
to the majority of women due to the low but significant risk of 
pregnancy loss. Several other studies of amniotic fluid proteome 
have been carried out, with a number of candidate biomarkers 
identified for predicting PTB and neonatal adverse outcomes 
secondary to intrauterine inflammation (155, 156), but these have 
not been clinically exploited (157).
A more acceptable, less invasive testing strategy based on 
analysis of cervico-vaginal fluids may have greater prognostic 
potential and acceptance. Gravett et al. (158) undertook a prot-
eomic study of the cervico-vaginal fluid in a non-human primate 
model of iatrogenic intra-amniotic infection, a major contributor 
to PTB, with the aim of identifying a non-invasive biomarker 
for this condition. Twenty-six proteins were found to be dif-
ferentially expressed in the presence of intra-amniotic infection 
compared to controls, with a preponderance of proteins involved 
in inflammatory regulation. Of these, IGFBP1 was increased 
16-fold in the presence of intra-amniotic infection, and this is a 
potential biomarker for clinical application. Many other studies 
have investigated levels of inflammatory cytokines and proteins 
in cervico-vaginal fluids, and candidate proteins such as IL-6 
have been consistently identified (159, 160), but these have not 
yielded biomarkers with sufficient prognostic utility to be useful 
clinically. Georgiou and colleagues employed proteomic analysis 
of cervico-vaginal fluid samples in at-risk asymptomatic women 
to identify candidate biomarkers of impending preterm delivery 
(161). They found that thioredoxin and interleukin 1 receptor 
antagonist levels were significantly reduced up to 90 days prior 
to preterm labor compared with women who delivered at term. 
Both proteins had a positive predictive value of >72% and 
negative predictive value of >95%. The prognostic value of these 
biomarkers has yet to be demonstrated in independent studies 
and populations; however, and to date, proteomic approaches 
have not yet yielded clinically useful tests that have been com-
mercialized and widely adopted (162).
PReCiSiON ReFiNeMeNT USiNG New 
TeCHNOLOGieS
“Omic” approaches may be suitable for both primary screening, 
as well as precision refinement in women previously identified 
as being at risk of PTB by other screening modalities (Figure 1). 
Gene–environment interactions underlie almost all responses 
of complex organisms to external stimuli. This principle is the 
basis of pharmacogenomics, whereby an individual’s genetic 
susceptibility to the effects of a drug determines whether or not 
that drug is used. However, this may be used on a larger scale 
than is currently employed in order to direct interventions in 
those who screen at increased risk of PTB. For example, women 
who are genetically more likely to succeed in smoking cessation 
with nicotine replacement therapy may be offered this interven-
tion, while those genetically likely to fail may avoid the potential 
adverse outcomes of this therapy (163).
As high-throughput genomic sequencing technology becomes 
more affordable and rapid and point-of-care devices are devel-
oped, future technological advances may provide exciting new 
avenues for further refinement of risk. Other risk factors likely 
to be amenable to “omic” precision refinement include bacterial 
dysbiosis, previous inflammatory and infection-related PTB, as 
well as cervical dysfunction (Figure 1).
Other technological advances are likely to be able to be exploited 
in the near future to gain greater precision in PTB prevention strat-
egies. Wearable mobile sensor technologies have been developed 
for a number of applications requiring real-time monitoring of 
physiological parameters that allow monitoring of health status/
responses and identification of individuals at risk. Examples include 
remote monitoring of the elderly after transfer to a community care 
setting (164, 165). Sophisticated systems have been developed and 
trialed for measuring multiple physiological parameters (166), 
and it could be envisaged that such systems could be adapted and 
used in high-risk women to identify changes in uterine activity, for 
example, suggestive of early onset of labor (164).
In addition, E-registries and web-based surveillance systems 
are exciting developments in health information systems that 
have applications in monitoring maternal health trends and 
outcomes together with changes in population characteristics and 
risks (167, 168). A simple example that illustrates the potential is 
the use of a mobile SMS-based system for monitoring maternal 
health in low-resource settings (169).
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